Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye fluid analysis may unlock secrets of rare eye condition

NCT ID NCT07506551

Knowledge-focused Sponsor: Prim. Prof. Dr. Oliver Findl, MBA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study examines proteins in the vitreous (the gel-like fluid inside the eye) of patients with pseudoexfoliation syndrome (PEX), a condition that can lead to glaucoma. Researchers will compare protein levels between eyes with and without PEX in 24 adults undergoing eye surgery for other reasons. The goal is to better understand the biology of PEX, not to test a treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal protein markers that help understand pseudoexfoliation syndrome, potentially pointing toward future diagnostic or treatment targets.
What could go wrong
This is a very small pilot study (24 participants) that only observes protein levels, not a treatment trial. It may not lead to any direct medical advances.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 105 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * PEX syndrome * Macular pucker or macular hole and scheduled for vitrectomy * Age 21 or older * Written informed consent prior to surgery Exclusion Criteria: * Previous vitrectomy or intravitreal application of drugs * Systemic anti-inflammatory drugs * Pre- surgical topical anti-inflammatory drugs (NSAR, Steroids) * Pre- surgical topical prostaglandins * Diabetic retinopathy * AMD * PEX Syndrome only in the contralateral eye (the eye not scheduled for surgery)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epiretinal membrane are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

exfoliation syndrome exfoliation syndrome, susceptibility to macular holes preretinal fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pseudoexfoliation syndrome

Contacts and locations

Locations

  • Vienna Institute for Research in Ocular Surgery (VIROS)

    Vienna, 1140, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.